Take a sneak peek at the in depth look into the successful first year of ACR Image Metrix, appearing in our November 2008 issue.
After its first year serving as a for-profit division of the American College of Radiology, ACR Image Metrix has succeeded in not only meeting its goal of six projects, but also doubling this goal by participating in 12 projects with 15 different sponsor organizations. "We take our scientific and academic learnings and tap into this knowledge to help communicate and help implement clinical research to gain approval for drugs and software," said Michael Morales, ACR Image Metrix general manager. Don’t miss our upcoming November issue when Applied Clinical Trials speaks with Morales to find out the background of the company, details of the growth it has experienced in the past year, and its plans for the future. Also, take a look below for the full press release from the company.
(Philadelphia, PA; September 23, 2008) – In its first full year of operation since it was launched as a for-profit division of the American College of Radiology, ACR Image Metrix exceeded its goals by initiating projects for over 12 drug and device companies.
“We are very pleased with the success of our business model as a state-of-the-art core lab and our validated IT platform,” said Stephen King, ACR Image Metrix chief operating officer. “There is a significantly higher level of awareness for the value imaging expertise can add to clinical trials, as well as a growing understanding of the role ACR Image Metrix can play in expediting clinical trials.”
“Our unique heritage borne out of the ACR and ACRIN organizations has shown to give us tremendous creditability from the start,” said Michael J. Morales, ACR Image Metrix general manager. “It positions us as having both the scientific and operational horsepower to compete at a very high level in the CRO marketplace.”
The ACR Image Metrix advantage resides within its access to the American College of Radiology, a 32,000-member professional organization, and to the ACR Imaging Network (ACRIN), which has participated in clinical trials ranging from 65 to more than 50,000 subjects and involving more than 500 million images.
Morales said that Image Metrix will concentrate on CROs, pharmaceutical, biotech, and medical device companies to provide services in Phase I-III clinical trials.
The state-of-the-art imaging core laboratories of Image Metrix provide clients access to the latest technologies including CT, MRI/MRS, and PET/nuclear medicine. Recent trials have focused on the capacity of molecular and functional imaging to serve as biomarkers of the effectiveness of anticancer treatments.
“We’re ahead of where we wanted to be in our growth strategy,” Morales said. “We’re looking forward to accelerated growth in year two.”
About Image Metrix
Image Metrix, a division of the American College of Radiology, is in the forefront of applying imaging techniques as a predictive and prognostic biomarker for clinical trials. The key to increasing the efficiency of drug development programs is the integration of the appropriate imaging modality.
The world-class team of physicians and scientists at ACR Image Metrix works with pharmaceutical, biotech and medical device companies to increase the efficiency of drug development programs by integrating the appropriate imaging modalities. Their years of experience and proven expertise in employing state-of-the-art technologies provide a complete line of imaging services.